Tahara M - Search Results

1

Effect of protein kinase Cbeta inhibitor on Ca2+ homeostasis in diabetic sensory neurons.

Tahara M, Omatsu-Kanbe M, Sanada M, Maeda K, Koya D, Matsuura H, Kashiwagi A, Yasuda H. Tahara M, et al. Neuroreport. 2006 Apr 24;17(6):683-8. doi: 10.1097/00001756-200604240-00026. Neuroreport. 2006. PMID: 16603936

2

[A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone].

Maeda K, Tatsumi M, Tahara M, Murata Y, Kawai H, Yasuda H. Maeda K, et al. Among authors: tahara m. Rinsho Shinkeigaku. 2005 Jun;45(6):416-21. Rinsho Shinkeigaku. 2005. PMID: 16022465 Japanese.

3

[A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].

Hayashi R, Tahara M, Oeda T, Konishi T, Sawada H. Hayashi R, et al. Among authors: tahara m. Rinsho Shinkeigaku. 2015;55(4):227-32. doi: 10.5692/clinicalneurol.55.227. Rinsho Shinkeigaku. 2015. PMID: 25904250 Japanese.

4

[Brain MRI findings in Japanese patients with clinically isolated syndrome].

Tanaka M, Motoyama R, Tahara M, Tanaka K. Tanaka M, et al. Among authors: tahara m. Rinsho Shinkeigaku. 2012;52(10):725-9. doi: 10.5692/clinicalneurol.52.725. Rinsho Shinkeigaku. 2012. PMID: 23064621 Japanese.

5

[A case of subacute myelitis with anti-aquaporin 4 antibody after thymectomy for myasthenia gravis: review of autoimmune diseases after thymectomy].

Kohsaka M, Tanaka M, Tahara M, Araki Y, Mori S, Konishi T. Kohsaka M, et al. Among authors: tahara m. Rinsho Shinkeigaku. 2010 Feb;50(2):111-3. doi: 10.5692/clinicalneurol.50.111. Rinsho Shinkeigaku. 2010. PMID: 20196494 Review. Japanese.

6

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.

7

CD8CD11a(high) cells decreased in multiple sclerosis but not in neuromyelitis Optica.

Matsui M, Tahara M, Tanaka M, Tanaka K, Matsui M, Konishi T. Matsui M, et al. Among authors: tahara m. Eur Neurol. 2010;63(3):159-63. doi: 10.1159/000283929. Epub 2010 Feb 16. Eur Neurol. 2010. PMID: 20160445

8

[Trial of rituximab in three patients with neuromyelitis optica].

Imamura H, Tanaka M, Kitagawa N, Tahara M, Oono M, Tanaka K, Konishi T. Imamura H, et al. Among authors: tahara m. Rinsho Shinkeigaku. 2009 Aug;49(8):457-62. doi: 10.5692/clinicalneurol.49.457. Rinsho Shinkeigaku. 2009. PMID: 19827593 Japanese.

9

Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply.

Tahara M, Oeda T, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Jul;19(7):564. doi: 10.1016/S1474-4422(20)30185-X. Lancet Neurol. 2020. PMID: 32562675 No abstract available.

10

Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.

Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Mult Scler Relat Disord. 2022 Apr;60:103730. doi: 10.1016/j.msard.2022.103730. Epub 2022 Mar 7. Mult Scler Relat Disord. 2022. PMID: 35287025 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

677 results

Search Page

Filters